Catalent and Grunenthal Announce Successful Collaboration to Facilitate Expedited Clinical Development Timelines
March 16, 2023
March 16, 2023
SOMERSET, New Jersey, March 16 -- Catalent Inc., a pharma, biotech and consumer health company, issued the following news on March 15, 2023:
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and Grunenthal, an international science-driven pharmaceutical company and a global leader in pain research and management, today announced their successful formulation design and clinical-phase manufacturing collaboration for an orally dose . . .
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and Grunenthal, an international science-driven pharmaceutical company and a global leader in pain research and management, today announced their successful formulation design and clinical-phase manufacturing collaboration for an orally dose . . .